Clinical Trials Logo

EGFR-TKI Resistant Mutation clinical trials

View clinical trials related to EGFR-TKI Resistant Mutation.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06071013 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Start date: September 28, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Nintedanib with EGFR-TKI in participants with advanced EGFR-TKI-resistant non-small cell lung cancer

NCT ID: NCT02972333 Not yet recruiting - Brain Metastases Clinical Trials

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Start date: December 2016
Phase: Phase 3
Study type: Interventional

The study aims to investigate the efficacy and safety of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI.

NCT ID: NCT02661009 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)

Start date: January 2016
Phase: N/A
Study type: Observational

In this clinical trial, investigators select FFPE and plasma samples of non-small cell lung cancer which are used for quantitative detection of four kinds of EGFR(Epidermal Growth Factor Receptor) mutations. By the following two aspects, investigators evaluate the clinical performance of the EGFR quantitative kits. 1. methodology validation: To certify the equivalence between the EGFR quantitative kit and the common used detection methods. 2. analysis of the relationship between the type and proportion of EGFR sensitive mutation and EGFR-TKI benefit.